Hit enter to search or ESC to close
NuView Life SciencesNuView Life SciencesNuView Life SciencesNuView Life Sciences
  • Home
  • About Us
    • Mission
    • Leadership
      • Management Team
      • Directors
      • Clinical Collaborators
      • Consultants
  • Products
    • In Vivo Diagnostics
    • In Vitro Diagnostics
    • Theranostics Applications
    • Why Research for New Diagnostics?
  • Pipeline
  • News
    • NuView Life Sciences in the News
    • Press Releases
  • Publications
  • Contact Us
NuView Life Sciences
All Posts By

Karla Jo Helms

Oct 05
Love0

NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer

By Karla Jo Helms News, Press Releases

Developing a Novel Approach for the Future of Breast Cancer Diagnosis and Treatment PARK CITY, UT / ACCESSWIRE / October 5, 2022 / NuView Life…

Read More
Aug 25
Love0

Jay Bishoff, MD, joins The Smith Institute for Urology

By Karla Jo Helms News

Building on a track record of 30 years of innovation in urological surgery and improved outcomes, Jay Bishoff, MD, joins The Smith Institute for Urology…

Read More
Feb 28
Love0

Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

By Karla Jo Helms Publications

Pardeep Kumar  1 , Sushil K Tripathi  1 , C P Chen  2 , Eric Wickstrom  3   4 , Mathew L Thakur  5   6   7  …

Read More
Feb 08
Love0

Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses

By Karla Jo Helms Press Releases

Modern cancer diagnosis tests and treatments are based on what works for adults. A new technology, NV-VPAC1(™), may help doctors better and more accurately diagnose…

Read More
Jan 19
Love0

Delfi Diagnostics reels in $100M for blood-based cancer test

By Karla Jo Helms News

Last updated: Jan. 14, 2021 By Meg Bryant Liquid biopsy startup Delfi Diagnostics Inc. scooped up $100 million in a series A round led by…

Read More
Jan 17
Love0

Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment

By Karla Jo Helms News

Recent major investments signal growth in an emerging therapeutic sector. Over the last 20 years there has been a tidal wave of innovation when it…

Read More
Nov 16
Love0

NuView Life Sciences Develops New Theranostics Approach to Offset High Cost of Cancer Diagnosis, Treatment

By Karla Jo Helms News, Press Releases

The high cost of diagnosing and treating cancer—in addition to the prescription drugs and therapies associated with the disease—is bankrupting hard-working Americans, who cannot afford…

Read More
Nov 12
Love0

Radiopharmaceuticals Gain Traction for Cancer Theranostics Potential

By Karla Jo Helms News

After decades of neglect from big pharma, radiopharmaceuticals are generating major oncology deals globally. This could lead to a boom in cancer drugs that can…

Read More
Aug 25
Love2

Park City company develops new ground breaking cancer treatment

By Karla Jo Helms News

Park City company develops new ground breaking cancer treatment By Press Release August 25, 2020 283 0 Comments Park City— To meet the demand for…

Read More
Aug 20
Love1

FSP and COVID-19: Impact on Clinical Trial Development

By Karla Jo Helms News

BY CHRIS BAKER, SENIOR VICE PRESIDENT AND GLOBAL HEAD OF FSP, PAREXEL & JOANNE SULLIVAN, GLOBAL HEAD OF SAFETY AND REGULATORY OUTSOURCING, PAREXEL & LISA…

Read More
1 2 3 … 6 Next

Categories

  • News
  • NuView Life Sciences in the News
  • Press Releases
  • Publications

Recent Posts

  • NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer
  • Targeting VPAC1 Receptors for Imaging Glioblastoma
  • NuView Life Sciences Creates Subsidiary for Latin American Market
  • Jay Bishoff, MD, joins The Smith Institute for Urology
  • Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

Archives

  • October 2022
  • January 2022
  • November 2021
  • August 2021
  • February 2021
  • January 2021
  • November 2020
  • August 2020
  • June 2020
  • May 2020
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • April 2019
  • March 2019
  • January 2019
  • November 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • March 2013
  • February 2013
  • February 2000
  • January 2000

NuView Life Sciences is a clinical stage oncology company addressing unmet medical needs.

Read More

Contact Address

NuView Life Sciences, Inc
1389 Center Drive, Suite 200
Park City, Utah 84098

Office: 435.647.9758 

Contact us:
admin@nuviewlifesciences.com

Media inquiries:
Jennifer K. Zimmons
jzimmons@zimmonsic.com

The most recent press

  • NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer October 5, 2022
  • NuView Life Sciences Creates Subsidiary for Latin American Market November 17, 2021

Quick Links

  • Home
  • About Us
  • Products
  • Pipeline
  • News
  • Publications

© 2023 NuView Life Sciences. Terms of Use

  • Home
  • About Us
    • Mission
    • Leadership
      • Management Team
      • Directors
      • Clinical Collaborators
      • Consultants
  • Products
    • In Vivo Diagnostics
    • In Vitro Diagnostics
    • Theranostics Applications
    • Why Research for New Diagnostics?
  • Pipeline
  • News
    • NuView Life Sciences in the News
    • Press Releases
  • Publications
  • Contact Us